About MEDRx
MEDRx is a publicly listed company based in Japan founded in 2002. Trans-dermal drug delivery technologies are developed for enhanced solubility. It operates in the Technology and Healthcare sectors. The company has 22 employees. Its chief executive, as recorded, is Yonehiro Matsumura. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science.
Company details
MEDRx was founded in 2002 in Yamaguchi, Japan, within the biotechnology sector. Focus is placed on transdermal systems like ILTS and NCTS to boost drug solubility and absorption. Products are created using these technologies, with the lead candidate CPN 101an α2 adrenergic agonist for treating muscle spasmscurrently in phase I clinical trials. Operations center on advancing therapeutic applications through such innovations.
- Headquarters Yamaguchi, Japan
- Employees 22
- Stage Public
- SectorsTechnologyHealthcare
- Phoneβ’β’β’β’ β’β’β’β’
- Website medrx.co.jp
- Legal Name Medrx Co., Ltd.
- Annual Revenue$817.5 K (USD)-50.34as on Dec 31, 2025
- Net Profit-$5.98 M (USD)-16.19as on Dec 31, 2025
- EBITDA-$5.92 M (USD)-22.99as on Dec 31, 2025
- Latest Funding Round$6.16M (USD), Post-IPO
Jun 2016
- Employee Count22
Funding Insights of MEDRx
- Total Rounds 1
- Last Round Post-IPO β $6.16M
- First Round $6.16M
(Jun 2016)
All 1 funding rounds of MEDRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $6.16M | Post-IPO | β | β | β |
People of MEDRx
1 people are tracked at MEDRx (1 in leadership); the tracked headcount is 22.
| Name | Role | Group |
|---|---|---|
Yonehiro Matsumura | CEO & President | Leadership |
Complete people profiles for MEDRx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MEDRx
MEDRx is a publicly listed company on the TSE with ticker symbol 4586 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Feb 2013
- Listed onTSE: 4586
- Listed entityMedrx Co., Ltd.
- Exchange sectorHealth technology
- ISINJP3921220004
- Share price56.00 JPY (-1.75% on the day) · 2026-10-14
- Market capitalisation3,990,433,136.00 JPY
- EPS (diluted, trailing year)-14.45 JPY
- Volume (last session)712,500
Financials of MEDRx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 128.1M JPY | -937.4M JPY | -928.1M JPY |
| 2024 | 257.9M JPY | -806.8M JPY | -754.6M JPY |
| 2023 | 29.5M JPY | -932.9M JPY | -888.0M JPY |
| 2022 | 59.5M JPY | -1.11B JPY | -1.05B JPY |
| 2021 | 8.3M JPY | -1.06B JPY | -1.00B JPY |
Detailed financial statements for MEDRx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of MEDRx
3 dated milestones of MEDRx across 14 years, from founding to its latest funding, stage changes and deals.
- Founded MEDRx is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $6.2M.
Web traffic of MEDRx
The website of MEDRx (medrx.co.jp) receives about 4.3K visits a month.
- Monthly visits4.3K
▼ 23.8% vs previous month
Websites whose visitors overlap most with MEDRx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| umnpharma.com | 100% | View details | |||
finance.yahoo.co.jp | finance.yahoo.co.jp | 96% | #530 | β | |
| peptidream.com | 94% | 41.6K | #741,291 | View details | |
| morningstar.co.jp | 89% | 2.4K | #7,940,037 | View details | |
kabuyoho.ifis.co.jp | kabuyoho.ifis.co.jp | 89% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 7 similar websites and full traffic analytics for MEDRx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medrx
Complete news archive for MEDRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MEDRx
MEDRx was founded in 2002 and raised its 1st funding round 14 years after it was founded.
MEDRx is headquartered in Japan. It is registered at Yamaguchi, Japan.
Yonehiro Matsumura is the CEO of MEDRx, as recorded in our data.
MEDRx has 22 employees.
Annual revenue of MEDRx is $817.5K as on Dec 31, 2025.
MEDRx was founded in 2002 in Yamaguchi, Japan, within the biotechnology sector. Focus is placed on transdermal systems like ILTS and NCTS to boost drug solubility and absorption. Products are created using these technologies, with the lead candidate CPN 101an Ξ±2 adrenergic agonist for treating muscle spasmscurrently in phase I clinical trials. Operations center on advancing therapeutic applications through such innovations.
Yes, MEDRx is publicly traded on TSE under the ticker symbol 4586.